Ligand id: 10469

Name: COVA322

No information available.
Summary of Clinical Use
COVA322 was advanced to Phase 1a/2b clinical evaluation in patients with stable chronic moderate-to-severe plaque psoriasis (NCT02243787). The agent was found to be unsafe and the trial was terminated.
Mechanism Of Action and Pharmacodynamic Effects
Dual TNF/IL-17A inhibition was proposed as a superior mechanism to achieve efficacy in diseases where activation of the pro-inflammatory Th17/IL-17 pathway limits the effectiveness of single agent TNF inhibition.